Exact Sciences Corporation (EXAS)
Exact Sciences Corporation (EXAS)
$114.88 USD
Updated Jul 19 12:00am
Add EXAS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 52 in Medical - Diagnostics/Research
See all “A” rated Strong Buy stocks
EXAS News Stream
| Event/Time | News Detail | Start | End | Change | |||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Top Stories View All
Best & Worst Performing Stock Industries for July 19, 2019
Best & Worst Performing Small Cap Stocks for July 19, 2019
Best & Worst Performing Mid Cap Stocks for July 19, 2019
Best & Worst Performing Mega Cap Stocks for July 19, 2019
Best & Worst Performing Large Cap Stocks for July 19, 2019
View All Top StoriesExact Sciences Corporation (EXAS) Company Bio
Exact Sciences is a molecular diagnostics company focused on gastrointestinal cancers. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The company was founded in 1995 and is based in Madison, Wisconsin.
EXAS Stock Chart More Charts
EXAS Price/Volume Stats
| Current price | $114.88 |
| Prev. close | $116.90 |
| Day low | $114.28 |
| Day high | $117.76 |
| 50-day MA | $108.09 |
| 200-day MA | $87.11 |
| 52-week high | $121.98 |
| 52-week low | $47.78 |
| Volume | 1,240,600 |
| Avg. volume | 1,696,899 |
| Dividend yield | N/A |
| Market Cap | 14.84B |
EXAS Returns
| 1-mo | -0.49% |
| 3-mo | 24.59% |
| 6-mo | 45.79% |
| 1-year | 69.89% |
| 3-year | 811.02% |
| 5-year | 589.56% |
| YTD | 82.06% |
| 2018 | 20.10% |
| 2017 | 293.26% |
| 2016 | 44.75% |
| 2015 | -66.36% |
| 2014 | 133.53% |
Loading social stream, please wait...